The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Rigshospitalet

Status: Unknown

Conditions: Urinary Bladder Neoplasm

Treatments: Other: Evaluation of muscle mass and muscle function

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04144270

70298

Details and patient eligibility

About

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent
• Age ≥ 18 år
• Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology
• ECOG performance status 0 - 3
• Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease).

Exclusion criteria

• Age < 18

Trial design

30 participants in 1 patient group

Included patients

Description:

One-arm study. All included patients will have muscle mass and muscle function evaluated

Treatment:

Other: Evaluation of muscle mass and muscle function